Sugi Predict

Sugi Predict / Compounds / SCHEMBL16554270

SCHEMBL16554270

SCHEMBL16554270

C=C(C)c1cccc(O[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 0.40
▸ CA1 P00915 4/20 0.40
▸ CA9 Q16790 4/20 0.40
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ TSHR P16473 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CES2 O00748 1/20 0.35
▸ CES1 P23141 1/20 0.35
▸ PAX8 Q06710 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL341880 0.84 KMT2A (0.53) CA12CA1CA9HSP90AA1HSP90AB1
SCHEMBL5336885 0.83 CA12 (0.38) CA12CA1CA9HSP90AA1HSP90AB1
SCHEMBL9507645 0.83 NPC1 (0.41) ALDH1A1NPC1RAB9ATSHRHTT
SCHEMBL14834242 0.83 CA12 (0.37) CA12CA1CA9
SCHEMBL31187414 0.83 NPC1 (0.41) ALDH1A1NPC1RAB9ATSHRHTT
SCHEMBL2989104 0.81 AKR1C3 (0.53) CA12CA1CA9HSP90AA1HSP90AB1
SCHEMBL7706827 0.80 CA1 (0.50) CA12CA1CA9HSP90AA1HSP90AB1
SCHEMBL4498801 0.80 PREP (0.43) CA12CA1CA9RAB9ATSHR
SCHEMBL2981524 0.79 HSP90AA1 (0.43) CA12CA1CA9HSP90AA1HSP90AB1
SCHEMBL25984931 0.79 PARP1 (0.58) CA12CA1CA9HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-11-30 — — US disclosed
CN-110804072-B Dioxolane analogues of uridine for use in the treatment of cancer 美迪维尔公司 2023-05-12 — — CN disclosed
CN-110790789-B Dioxolane analogues of uridine for use in the treatment of cancer 美迪维尔公司 2023-05-12 — — CN disclosed
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-04-20 — — US disclosed
US-11447511-B2 Dioxolane analogues of uridine for the treatment of cancer MEDIVIR AB (SE) 2022-09-20 — — US disclosed
EP-3572410-B1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2022-07-20 — — EP disclosed
US-20210054008-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2021-02-25 — — US disclosed
US-10822360-B2 Dioxolane analogues of uridine for the treatment of cancer MEDIVIR AB (SE) 2020-11-03 — — US disclosed
US-20200239502-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2020-07-30 — — US disclosed
US-10654877-B2 Dioxolane analogues of uridine for the treatment of cancer MEDIVIR AB (SE) 2020-05-19 — — US disclosed
US-9540411-B2 HCV polymerase inhibitors MEDIVIR AB (SE) 2017-01-10 — — US disclosed
US-20160340380-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2016-11-24 — — US disclosed
US-9481703-B2 HCV polymerase inhibitors MEDIVIR AB (SE) 2016-11-01 — — US disclosed
US-20160271160-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2016-09-22 — — US disclosed
EP-3057976-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2016-08-24 — — EP disclosed
EP-3041855-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2016-07-13 — — EP disclosed
WO-2016030335-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2016-03-03 — — WO disclosed
US-20150175648-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-06-25 — — US disclosed
WO-2015056213-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-04-23 — — WO disclosed
WO-2015034420-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239502-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR CA12 3689/4885CA1 4799/4885CA9 3720/4885
US-20160271160-A1 HCV POLYMERASE INHIBITORS POLI, POLB, POLL CA12 4101/4885CA1 4835/4885CA9 3492/4885
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NT5C CA12 3451/4885CA1 4735/4885CA9 3567/4885
US-10654877-B2 Dioxolane analogues of uridine for the treatment of cancer ADORA3, DUT, NTPCR CA12 3689/4885CA1 4799/4885CA9 3720/4885
US-20150175648-A1 HCV POLYMERASE INHIBITORS POLI, POLB, POLL CA12 4101/4885CA1 4835/4885CA9 3492/4885
US-20160340380-A1 HCV POLYMERASE INHIBITORS POLI, POLB, POLL CA12 4101/4885CA1 4835/4885CA9 3492/4885
US-20210054008-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR CA12 3689/4885CA1 4799/4885CA9 3720/4885
US-11447511-B2 Dioxolane analogues of uridine for the treatment of cancer ADORA3, DUT, NTPCR CA12 3689/4885CA1 4799/4885CA9 3720/4885
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR CA12 3689/4885CA1 4799/4885CA9 3720/4885
US-10822360-B2 Dioxolane analogues of uridine for the treatment of cancer ADORA3, DUT, NTPCR CA12 3689/4885CA1 4799/4885CA9 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.